Rutgers & Horizon plan to commercialize CRISPR base editing technology
Category: #health  By Saipriya Iyer  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Rutgers & Horizon plan to commercialize CRISPR base editing technology

Horizon has also agreed to fund further research in base editing at the Rutgers University.

Horizon Discovery Group plc, one of the globally reputed gene editing industry contenders, has reportedly inked a partnership with The State University of New Jersey, Rutgers. As per reliable sources, the agreement has been forged for developing and commercializing a gene editing technology – called base editing, that finds applications in new cell therapy development and is expected to augment Horizon’s research tools and services.

Credible reports cite that Horizon will join hands with the Rutgers University to develop the novel base editing platform from Dr. Shengkan Jin laboratory. As a part of the agreement, Horizon has already made a non-material payment to Rutgers, garnering the option to exclusively license the base editing technology to be used in all therapeutic applications. Sources familiar with the knowledge of the matter also claim that Horizon will fund further research in base editing at the Rutgers University while simultaneously undertaking evaluation and proof-of-concept studies at Horizon.

A report published by Genomeweb claims Terry Pizzie, CEO, Horizon, to have stated that base editing is one of the most potentially transformative of all gene editing technologies and is equipped with the ability to target numerous diseases that so far have no treatment. As a global leader in the field of gene modulation and gene editing, both in the applied as well as research markets, Horizon is rather thrilled to join forces with the Rutgers University, Pizzie added.

Further commenting on the partnership, Pizzie said that by extending Horizon’s scientific and IP capabilities, the company will now be more than able to completely support its pharma, academic, and biotech partners to deliver enhanced cell therapy solutions to patients. Also, as a part of its five-year investment strategy, Horizon is committed to pouring in capital in high-grade technologies which maintain its market leadership – base editing technology being the case in point, he elaborates.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Elevon set to buy Sage Pay to enhance its reach to global customers
Elevon set to buy Sage Pay to enhance its reach to global customers
By Saipriya Iyer

As the world is progressing towards digitalization, the e-commerce is gaining widespread traction across the globe. Keeping the progress of e-commerce alive, various companies worldwide are investing into the M&As....

Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
Triple Gene releases Phase 1 study data for INXN-4001 in heart failure
By Saipriya Iyer

Triple Gene LLC- a U.S. based cardiovascular gene therapy enterprise recently furnished preliminary data from its Phase 1 trial of INXN-4001, an investigational therapeutic candidate used in the treatment of cardiac fa...

Alibaba plans to offer bitcoin rewards to shoppers through Lolli
Alibaba plans to offer bitcoin rewards to shoppers through Lolli
By Saipriya Iyer

 

  • Now Alibaba shoppers can earn free bitcoin when they purchase products on Alibaba's e-commerce platform
  • Reportedly, the partnership would enable shoppers...